Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
← catalyst calendarNCT05739981 · readout in 314 d
Sponsored by Imunon (industry) · IMNN — their whole pipeline →. With Breakthrough Cancer Research.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
30estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-10 | actual | When the study began enrolling |
| Primary completion | 2027-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
Interventions
- Drug: Paclitaxel
- Drug: Carboplatin
- Drug: Bevacizumab
- Drug: IMNN-001
Primary outcome
what the primary-completion date above is the date OFMinimal Residual Disease
measured 8 months
Permalink · IMNN's whole pipeline · Catalyst calendar · Every registered study · What changed